Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Hammel P, et al. Among authors: bouche o. JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324. JAMA. 2016. PMID: 27139057 Clinical Trial.
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Andre T, et al. Among authors: bouche o. J Clin Oncol. 2003 Aug 1;21(15):2896-903. doi: 10.1200/JCO.2003.10.065. J Clin Oncol. 2003. PMID: 12885807 Clinical Trial.
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Bouché O, et al. J Clin Oncol. 2004 Nov 1;22(21):4319-28. doi: 10.1200/JCO.2004.01.140. J Clin Oncol. 2004. PMID: 15514373 Clinical Trial.
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.
Dahan L, Atlan D, Bouché O, Mitry E, Ries P, Artru P, Richard K, Lledo G, Nguyen T, Rougier P, Seitz JF. Dahan L, et al. Among authors: bouche o. Gastroenterol Clin Biol. 2005 Jan;29(1):11-5. doi: 10.1016/s0399-8320(05)80688-8. Gastroenterol Clin Biol. 2005. PMID: 15738890 Free article.
Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Barbare JC, et al. Among authors: bouche o. J Clin Oncol. 2005 Jul 1;23(19):4338-46. doi: 10.1200/JCO.2005.05.470. J Clin Oncol. 2005. PMID: 15994145 Clinical Trial.
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Bonnetain F, Bouché O, Conroy T, Arveux P, Raoul JL, Giovannini M, Etienne PL, Mitry E, Seitz JF, Rougier P, Girault C, Bedenne L; FFCD (Fédération Francophone de Cancérologie Digestive). Bonnetain F, et al. Among authors: bouche o. Gastroenterol Clin Biol. 2005 Nov;29(11):1113-24. doi: 10.1016/s0399-8320(05)82175-x. Gastroenterol Clin Biol. 2005. PMID: 16505756 Free article. Clinical Trial.
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Gérard JP, et al. Among authors: bouche o. J Clin Oncol. 2006 Oct 1;24(28):4620-5. doi: 10.1200/JCO.2006.06.7629. J Clin Oncol. 2006. PMID: 17008704 Clinical Trial.
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A. André T, et al. Among authors: bouche o. J Clin Oncol. 2007 Aug 20;25(24):3732-8. doi: 10.1200/JCO.2007.12.2234. J Clin Oncol. 2007. PMID: 17704423 Clinical Trial.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. Lièvre A, et al. Among authors: bouche o. J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906. J Clin Oncol. 2008. PMID: 18202412
408 results